

1 Efficacy and Viral Dynamics of Tecovirimat in Patients with MPOX: A Multicenter Open-Label,

2 Double-Arm Trial in Japan

3

4 Yutaro Akiyama^a, Shinichiro Morioka^{a, b, c, *}, Shinya Tsuzuki^{a, b, d}, Tomoki Yoshikawa^e, Masaya

5 Yamato^f, Hideta Nakamura^g, Masayuki Shimojima^e, Mizue Takakusaki^a, Sho Saito^a, Kozue

6 Takahashi^a, Mio Sanada^a, Mika Komatsubara^a, Kahoru Takebuchi^a, Etsuko Yamaguchi^a, Tetsuya

7 Suzuki^{a, c, h}, Komei Shimokawaⁱ, Takeshi Kurosu^e, Madoka Kawahara^e, Kohei Oishi^e, Hideki

8 Ebihara^e, Norio Ohmagari^{a, b}

9

10 ^aDisease Control and Prevention Center, National Center for Global Health and Medicine

11 Hospital, Tokyo, Japan

12 ^bAMR Clinical Reference Center, National Center for Global Health and Medicine Hospital,

13 Tokyo, Japan

14 ^cEmerging and Reemerging Infectious Diseases, Graduate School of Medicine, Tohoku

15 University, Sendai, Japan

16 ^dFaculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium

17 ^eDepartment of Virology I, National Institute of Infectious Diseases, Tokyo, Japan

18 ^fDivision of General Internal Medicine and Infectious Diseases, Rinku General Medical Center,

19 Izumisano, Japan

20 ^gDivision of Infectious, Respiratory, and Digestive Medicine, University of the Ryukyus

21 Graduate School of Medicine

22 ^hDepartment of Infectious Diseases, Faculty of Medicine, University of Yamanashi, Yamanashi,

23 Japan

24 ⁱDivision of Pharmacy, National Center for Global Health and Medicine Hospital, Tokyo, Japan

25

26 All authors meet the ICMJE authorship criteria.

27

28 **Corresponding author:**

29 *Shinichiro Morioka

30 Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital

31 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan

32 Telephone: +81-3-3202-7181

33 Fax: +81-3-6228-0738

34 E-mail: shmorioka@hosp.ncgm.go.jp

35

36 **Keypoints:** The Tecopox study revealed that early tecovirimat administration might reduce viral
37 shedding duration, thereby mitigating infection spread. Moreover, patients infected with HIV
38 appeared to have prolonged viral shedding, increasing the transmission risk compared to those
39 without HIV.

40

41 **Abstract**

42 **Introduction:** Tecovirimat's application in treating mpox remains under-researched, leaving gaps
43 in clinical and virological understanding.

44 **Methods:** The Tecopox study, conducted in Japan, assessed the efficacy and safety of oral
45 tecovirimat therapy in patients with smallpox or mpox. Patients with mpox enrolled between June
46 28, 2022, and April 30, 2023, were included. We gathered demographic and clinical details along
47 with blood, urine, pharyngeal swab, and skin lesion samples for viral analysis. A multivariable
48 Tobit regression model was employed to identify factors influencing prolonged viral detection.

49 **Results:** Nineteen patients were allocated to the tecovirimat group. The median age was 38.5
50 years, and all were male. Ten patients (52.6%) were infected with the human immunodeficiency
51 virus (HIV). Sixteen patients (84.2%) had severe disease. Nine of the 15 patients (60.0%) (four
52 patients withdrew before day 14) had negative PCR results for skin lesion specimens 14 days
53 after inclusion. The mortality rates on days 14 and 30 were 0% and 0%, respectively. No severe
54 adverse events were reported. HIV status and the number of days from symptom onset to
55 tecovirimat administration were associated with lower Ct values ($p = 0.027$ and $p < 0.001$,
56 respectively). The median number of days when PCR testing did not detect the mpox virus in
57 each patient was 19.5 days.

58 **Conclusion:** The results suggest that early tecovirimat administration might reduce viral

59 shedding duration, thereby mitigating infection spread. Moreover, patients infected with HIV
60 appeared to have prolonged viral shedding, increasing the transmission risk compared to those
61 without HIV.

62

63 **Keywords:** mpox, tecovirimat, efficacy, safety, prolonged viral shedding

64

65 **1. Introduction**

66

67 As of April 2023, there has been a global reduction in the number of mpox (formerly known as
68 monkeypox) infections. However, the Western Pacific region, especially countries like Japan,
69 South Korea, and China, has witnessed a surge, primarily affecting males [1]. The application of
70 tecovirimat in treating mpox has not been extensively documented in terms of its clinical course
71 or viral load. For instance, among 150 patients with mpox, only two had a history of tecovirimat
72 treatment. Both patients received the medication during hospitalization and were human
73 immunodeficiency virus (HIV)-positive with suppressed viral loads [2].

74 The duration for which infectious mpox viruses can be detected may vary, with factors
75 such as symptom duration and treatment administration [3]. Nevertheless, there is a scarcity of
76 clinical and virological data regarding the use of tecovirimat for mpox treatment. In a clinical
77 study involving 1,750 patients, 355 individuals were treated with tecovirimat, while three
78 individuals were administered brincidofovir [4]. However, these studies did not assess the viral
79 load in the patients. The absence of viral load evaluation in these studies could limit the
80 assessment of the effectiveness of tecovirimat and brincidofovir as treatments for mpox.

81 Measurement of viral load is imperative for comprehending its replication and
82 dissemination within the body, as well as for gauging the impact of antiviral medications on

83 suppressing the virus. Further research and clinical studies that incorporate assessments of viral
84 load may offer comprehensive insights into the efficacy of tecovirimat in treating mpox.
85 Additionally, monitoring viral load levels could prove valuable in determining the duration of
86 viral shedding in patients with varying degrees of disease severity.

87

88 **2. Methods and analysis**

89

90 **2.1. Study design and settings**

91

92 This was a retrospective study involving patients enrolled in the Tecopox study, which is a
93 multicenter, open-label, double-arm trial conducted in Japan (Sapporo, Sendai, Tokyo, Aichi,
94 Osaka, Fukuoka, and Okinawa) that evaluates the efficacy and safety of oral tecovirimat therapy
95 for individuals with smallpox or mpox [5]. Enrollment began with the release of the research
96 database (jRCT, Trial ID: jRCTs031220169) on June 28, 2022, and is scheduled to continue until
97 March 31, 2024. The current study specifically included patients with mpox enrolled in the
98 Tecopox study between June 28, 2022, and April 30, 2023.

99

100 **2.2 Participants**

101

102 Participants in the Tecopox study were required to meet one to three or all of the following

103 criteria:

104

105 1. Obtain written informed consent.

106 2. Weigh at least 13 kg at the time of providing consent.

107 3. Have a definitive diagnosis of smallpox or mpox, confirmed by positive polymerase chain

108 reaction (PCR) results from patient specimens.

109 4. Consent to hospitalization from the start until resolution of the skin lesion.

110 5. If in the administered group, consent to hospitalization until completion of the 14-day oral

111 tecovirimat therapy.

112 Patients were excluded from the study if they had any of the following conditions:

113 1. A history of anaphylaxis to oral tecovirimat or any of its components.

114 2. Considered unsuitable by the primary investigator.

115 The Tecopox study consisted of two groups: the Tecovirimat and the Control.

116 Participants voluntarily chose the group they wished to join.

117

118 Tecovirimat group: Participants received 14 days of standard supportive care and oral tecovirimat

119 (body weight 13 to <25 kg, 200 mg; 25 to <40 kg, 400 mg; \geq 40 kg, 600 mg). Oral tecovirimat was
120 administered within 30 minutes of a moderate-to-high-fat meal.

121 Control group: Participants received supportive care only.

122

123 The Japanese Ministry of Health, Labor and Welfare (MHLW) obtained tecovirimat
124 from a pharmaceutical company, and the study drug was distributed free of charge to each site. If
125 participants wished to switch groups, they could do so by withdrawing their consent and rejoining
126 another group. In such cases, participants in the tecovirimat group stopped taking oral tecovirimat
127 at the time of withdrawal. Since all participants remained in the hospital during the intervention,
128 no specific strategies were employed to improve adherence. All concomitant care and
129 medications were allowed as clinically indicated.

130

131 **2.3. Data collection and measurement**

132

133 Data were collected on the following patient characteristics: date of birth, age, sex, body weight,
134 race, occupation, medical history, current medications, allergies, history of smallpox vaccination,
135 international travel and sexual contact within the last six months. Samples, including blood, urine,
136 pharyngeal swabs, and skin lesions, were collected for viral examination. For skin lesions,

137 contents from blisters, pustules, and crusts were carefully selected and gathered in accordance
138 with the National Institute of Infectious Diseases (NIID) manual [6]. The most severe skin rash
139 was chosen for sampling. While only one rash was typically selected, multiple samples could be
140 obtained if a patient had several rashes of similar severity, or if a new, more severe lesion emerged
141 during the clinical course. These samples were collected before the first dose of tecovirimat in the
142 treatment group or on the same day of participation in the control group.

143 Patients were assessed both clinically and daily for adverse events through medical
144 examinations and interviews, which included evaluations of their general condition and any skin
145 lesions. Their general condition was categorized by a researcher as bedridden, weakly ambulatory,
146 or fully ambulatory. Safety evaluations were conducted on days 3, 7, 10, and 14 through blood
147 tests, encompassing white blood cell and differential counts, hemoglobin levels, platelet counts,
148 total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine, and
149 blood sugar levels. For efficacy evaluation, samples of blood, urine, throat swabs, and skin lesions
150 were collected for viral testing. These were repeated on days 21, 30, 60, and 120. Additionally,
151 semen samples were collected for viral testing on days 60 and 120. If a patient found it
152 challenging to visit the hospital, medical examinations and interviews could be substituted with
153 remote methods, such as telephone interviews. In such cases, the collection of physical samples
154 was waived.

155 Blood testing was conducted at each hospital using equipment standard in clinical
156 settings. All specimens designated for viral testing were stored at temperatures at 2–8 °C after
157 collection and during transport. Alternatively, if immediate shipment was not possible, specimens
158 were stored frozen at temperatures below –20 °C, and preferably below –80 °C, before being
159 transported to the NIID. The copy numbers of the mpox virus were quantified using specific
160 multiplex quantitative PCR (qPCR). The qPCR targeted the F3L gene of the mpox virus, utilizing
161 the following primer and probe sets: forward primer (CATCTATTATAGCATCAGCATCAGA),
162 reverse primer (GATACTCCTCCTCGTTGGTCTAC), and probe
163 (HEX-TGTAGGCCGTGTATCAGCATCCATT-BHQ). Total nucleic acids were extracted from
164 200 µL samples using a high pure viral nucleic acid kit (Roche Applied Science), following the
165 manufacturer's protocols, with an elution volume of 50 µL. The qPCR assay involved adding 3 µL
166 of the extracted nucleic acid solution to 23 µL of a reaction mixture containing 2x QuantiTect
167 probe PCR master mix, water provided in the QuantiTect probe PCR kit (Qiagen, Hilden,
168 Germany), and 0.2 µM of each specific primer and probe. The process was performed on a
169 LightCycler 96 (Roche, Basel, Switzerland) with the following conditions: an initial 95 °C for 10
170 min, followed by 45 cycles of 95 °C for 15 s and 63 °C for 60 s. This method was validated using
171 mpox virus preserved by the NIID.

172 An independent researcher, free of conflicts of interest, monitored the data. The monitor

173 was chosen from the researchers of the principal investigating institution and had no connection
174 to this study. All adverse events equivalent to CTCAE version 5.0 Grade 3 or higher were
175 recorded, and the relationship between the event and the study was determined.

176

177 **2.4. Primary and secondary endpoint**

178

179 The primary endpoint of this study is the proportion of patients exhibiting a cycle threshold (Ct)
180 value of 40 or higher in PCR testing of skin lesions at 14 days following enrollment. Secondary
181 endpoints encompass the mortality rate at 14 and 30 days; viral load measurements in blood,
182 throat swabs, skin lesions, and urine at 14, 21, 30, 60, and 120 days; viral load in semen at 60 and
183 120 days; the duration of fever (≥ 37.5 °C) starting from the time of enrollment; general condition
184 upon entry, and at 14 and 30 days post-enrollment; and the incidence of adverse events. If more
185 than one skin lesion sample was collected from a participant on the same day, the sample with the
186 lowest Ct value was selected for analysis. Additionally, the study explored factors associated with
187 the Ct values of the skin lesion samples by employing a multivariable regression model.

188

189 **2.5. Statistical analysis**

190

191 For continuous variables, all patient characteristics as mentioned in section 2.3 were expressed as
192 median and interquartile range (IQR), while categorical variables were represented by absolute
193 values (n) with corresponding percentages (%). We investigated factors associated with
194 prolonged viral detection using a multivariable Tobit regression model. Factors included in this
195 analysis were the HIV status, severity of symptoms due to mpox, the number of days from
196 symptom onset to the day of PCR testing, and the number of days from symptom onset to
197 tecovirimat administration. The dependent variable was the Ct value of skin lesion samples, with
198 the upper limit set at 45. Ct values greater than 45 were classified as "not detected (n.d.)". In the
199 Tobit model, n.d. values were read as 45 and considered censored. Statistical significance was
200 determined by two-sided p-values less than 0.05. The Tobit model analysis was conducted using
201 R version 4.3.0 [7].

202

203 **3. Results**

204

205 A total of 27 patients were assessed for eligibility (**Figure 1**). Among these, 19 patients were
206 allocated to the tecovirimat group, and their demographic and clinical characteristics are
207 summarized in **Table 1**. Within this group, 17 patients (89.4%) were Asian, with a median age of
208 38.5 years, and all were male. Ten patients (52.6%) were infected with the human

209 immunodeficiency virus (HIV), and 13 patients (68.4%) had a history of sexually transmitted
210 diseases. None of the patients had received a smallpox vaccination before the infection. Sixteen
211 patients (84.2%) were categorized as having severe disease, although none had any previously
212 identified risk factors for severe disease. The symptoms upon admission included a rash (94.7%),
213 fever (36.8%), lymphadenopathy (42.1%), malaise (42.1%), severe weakness (38.5%), headache
214 (38.5%), and rectal pain (42.1%). The observed rash sites were the genitals (27.8%), perianal
215 region (44.4%), arms (66.7%), face (66.7%), legs (66.7%), and trunk (77.8%).

216

217 **3.1. Primary and secondary endpoints**

218

219 The clinical outcomes for the patients enrolled in the study are summarized in **Table 2**. Out of the
220 participants, five (31.3%) withdrew from the study. With regard to the primary endpoint, nine out
221 of 15 patients (60.0%) (four patients withdrew before day 14) exhibited negative PCR results for
222 skin lesion specimens 14 days post-inclusion. Concerning secondary endpoints, the mortality
223 rates were 0% on both days 14 and 30. No severe adverse events were reported, and only one
224 participant experienced a non-severe adverse event, with none attributed to tecovirimat. The
225 median duration of hospitalization was 14 days, while the median time from rash onset to
226 disappearance of rash was 24 days. The median number of days from symptom onset to viral

227 DNA clearance when PCR testing did not detect the mpox virus in each patient was 19.5 days.

228 The number of samples collected during the Tecopox trial is detailed in **Appendix 1**, and the

229 results of the viral load in the blood, throat swab, skin lesion, and urine at 14, 21, 30, 60, and 120

230 days, as well as the viral load in semen at 60 and 120 days for each participant, are provided in

231 **Appendix 2**. At the time of study enrollment, mpox virus DNA was detected in 17 cases (89.5%)

232 in skin lesions, 11 cases (57.9%) in throat swabs, 10 cases (52.6%) in blood, and 7 cases (36.8%)

233 in urine. The viral load in the blood, throat swabs, skin lesions, and urine tended to be at its

234 highest upon enrollment, followed by a gradual decrease. No virus was detected in the semen

235 samples on days 60 and 120.

236

237 **3.2. Results of Tobit regression model analysis**

238

239 HIV status and the time elapsed from symptom onset to tecovirimat administration were

240 correlated with lower Ct values ($p = 0.027$ and <0.001 , respectively). Conversely, the number of

241 days from symptom onset to PCR testing was associated with higher Ct values ($p < 0.001$). The

242 details of the analysis are presented in **Table 3**, and the predicted Ct values, corresponding to the

243 interval from the day of symptom onset to the day of PCR testing, are illustrated in **Figure 2**.

244

245 **3.3. Description of a case with a typical clinical course**

246

247 In this account, we detail the case of a Japanese man in his 30s who required an extended hospital
248 stay due to a persistent rash. The patient, who had a previous history of syphilis, developed
249 fatigue, fever, and a generalized skin rash after engaging in unprotected sexual activity with men
250 seven days prior to the onset of symptoms. Mpox was diagnosed through a PCR test result from a
251 rash swab. Although his fever subsided two days after diagnosis, the rash spread across his body,
252 accompanied by gradually worsening perianal pain. He was admitted to our hospital five days
253 post-diagnosis and was enrolled in the Tecopox trial. Upon admission, he experienced severe
254 perianal pain and ulcerated lesions. A rectal swab specimen tested positive for *Chlamydia*
255 *trachomatis* via PCR. Starting from the day of admission (day 0), he was treated with tecovirimat
256 600 mg twice daily for 14 days for mpox and doxycycline 100 mg twice daily for seven days for
257 chlamydial proctitis. Pain relief for the anal region was provided through the administration of
258 tramadol and non-steroidal anti-inflammatory drugs. On day 14, the patient finished the
259 prescribed course of tecovirimat, and the rash cleared. However, the anal ulcer persisted,
260 preventing discharge. MPOX PCR testing of the anal region, performed on day 19, returned
261 positive results. The patient was finally discharged on day 29, following the resolution of the anal
262 ulcer.

263

264 **4. Discussion**

265

266 In this study, we detail the clinical progression of 19 patients with mpox and explore viral
267 clearance throughout the illness. We discovered that extended viral detection was correlated with
268 HIV status and the time between symptom onset and tecovirimat administration. This
269 relationship was inversely correlated with the time from symptom onset to the day of PCR
270 testing.

271 In our dataset, the median days from symptom onset to viral DNA clearance when PCR
272 testing no longer detected the mpox virus in individual patients was 19.5 days (since PCR testing
273 was not conducted daily, the actual day may be slightly earlier). This number is smaller than that
274 found in a previous study [8] but greater than that in another study [9]. Such findings hint that
275 tecovirimat's effect on the duration of viral shedding remains ambiguous. Nevertheless, our
276 insights from the analysis suggest that administering tecovirimat earlier may reduce the viral
277 shedding duration. While viral DNA detection does not equate to infectivity, it is anticipated to
278 hinder the spread of the infection [5].

279 In our research, extended viral detection was linked to HIV status. Past reports did not
280 show any difference in treatment results, such as time to improvement or persistent symptom

281 rates, between patients with or without HIV [10]. This suggests that patients with HIV may
282 experience prolonged viral shedding, thereby increasing transmission risk, even though clinical
283 outcomes are consistent between both groups.

284 In another study, high concentrations of the mpox virus in the blood correlated with a
285 severe clinical course [11]. However, this study revealed that extended viral detection in skin
286 lesions did not correlate with mpox severity, though this relationship might become significant
287 with a larger sample size.

288 The virus in the semen at 60 and 120 days for eight patients, and at 60 days for one
289 patient, was undetectable. These findings align with the observation that mpox viral DNA was
290 undetectable in all three patients during tecovirimat therapy [12]. The results fortify the
291 evidence that the virus remained undetectable after treatment, suggesting a reduced transmission
292 risk for patients who completed tecovirimat therapy.

293 Our study had several limitations. Firstly, the absence of randomization in group
294 selection by the participants is a substantial limitation [5], leading to significant allocation
295 imbalance and making an accurate evaluation of tecovirimat therapy's efficacy challenging. The
296 study's open-label design may also introduce bias in the efficacy and safety assessment, although
297 we believe the bias was minimal since most primary and secondary outcomes were objectively
298 determined [5]. Secondly, we could not evaluate the clinical outcome of HIV patients with

299 CD4+ counts below 200/ μ l who underwent tecovirimat therapy. Thirdly, in a previous report,
300 skin lesions appeared at a median of 13 days post-treatment with tecovirimat for mpox. Among
301 six patients tested for orthopoxvirus post-treatment, one tested positive [14]. However, we did
302 not assess post-treatment skin lesions in this study. Therefore, further research is necessary to
303 examine these aspects in greater detail.

304

305 **5. Conclusions**

306 We detail the clinical progression of 19 patients with mpox, investigate the timeline of viral
307 clearance throughout the illness, and identify factors linked to extended viral detection. Our
308 findings suggest that administering tecovirimat earlier may reduce the duration of viral shedding,
309 thereby minimizing infection spread. The study indicates that patients with HIV experienced
310 prolonged viral shedding, leading to a heightened risk of transmission compared to those without
311 infection.

312

313 **Conflicts of interest:** None.

314

315 **Acknowledgements:** We are grateful to Yusuke Asai for his beneficial suggestions.

316

317 **Funding:** This work was supported by the MHLW “Research on Emerging and Re-emerging
318 Infectious Diseases and Immunization” Program (grant number 20HA2005 to SM) and the Japan
319 Agency for Medical Research and Development “Research Project to Promote the Development
320 of Innovative Medicines for Emerging and Re-emerging Infectious Diseases” (grant number
321 JP22fk0108502 to SM).

322

323 **Author contributions:** YA, SM, and ST drafted the manuscript. ST performed the statistical
324 analysis. MT, KT, MS, MK, YA, SM, SS, and TS prepared documents for the patients and ensured
325 ethical approval of the study. HE, TY, and MS advised on the sampling methods and viral
326 examinations. NO and SM supervised. All authors participated in the development of the study
327 protocol and approved the final version of the manuscript.

328

329 **Ethics approval and consent to participate:** This study was reviewed and approved by the
330 Ethics Committee of the Center Hospital of the National Center for Global Health and Medicine
331 (NCGM-C-004505-03). Informed consent was obtained from all participants. All procedures
332 were performed in accordance with the principles of the Declaration of Helsinki.

333

334 **Availability of data and materials:** All data generated or analyzed during this study are included

335 in this published article and its supplementary information files.

336

337 **References**

338

339 1. WHO. Multi-country outbreak of mpox, External situation report#21. Available at:

340 <https://www.who.int>. Accessed 27 April 2023.

341 2. Pilkington V, Quinn K, Campbell L, et al. Clinical presentation of MPOX in people with and

342 without HIV in the United Kingdom during the 2022 global outbreak. *AIDS Res Hum*

343 *Retroviruses*, 2023.

344 3. Callaby H, Emery K, Killip M, et al. Monkeypox virus isolation from longitudinal samples

345 from four patients to infer risk of onwards transmission: an interim analysis. *The Journal of*

346 *hospital infection*, 2023 ;135:139-44. DOI: 36958701.

347 4. Fox T, Gould S, Princy N, et al. Therapeutics for treating mpox in humans. *Cochrane*

348 *Database Syst Rev*, 2023 ; 3: CD015769.

349 5. Suzuki T, Saito S, Tsuzuki S, et al. Protocol of Tecopox study: a multicentre, open-label,

350 double-arm trial to evaluate the efficacy and safety of oral tecovirimat therapy for patients with

351 smallpox or monkeypox. *BMJ Open*, 2023 ; 13(8): e069550.

352 6. National Institute for Infectious Diseases. Byogentai Kenshutsu manual, Monkeypox (manual

- 353 for pathogen detection method, Monkeypox). Available at:
- 354 <https://www.niid.go.jp/niid/ja/labomanual.html#monkeypox>. Accessed 10 August 2023.
- 355 7. R Core Team. R: A Language and Environment for Statistical Computing 2018. Accessed 10
- 356 August 2023.
- 357 8. Suñer C, Ubals M, Tarín-Vicente EJ, et al. Viral dynamics in patients with monkeypox
- 358 infection: a prospective cohort study in Spain. *Lancet Infect Dis*, 2023 ; 23(4): 445-453.
- 359 9. Edman-Wallér J, Jonsson O, Backlund G, et al. Results of PCR Analysis of Mpox Clinical
- 360 Samples, Sweden, 2022. *Emerg Infect Dis*, 2023 ; 29(6): 1220-1222.
- 361 10. McLean J, Stoeckle K, Huang S, Berardi J, et al. Tecovirimat Treatment of People With HIV
- 362 During the 2022 Mpox Outbreak : A Retrospective Cohort Study. *Ann Intern Med*, 2023 ; 176(5):
- 363 642-648.
- 364 11. Hermanussen L, Grewe I, Tang HT, et al. Tecovirimat therapy for severe monkeypox
- 365 infection: Longitudinal assessment of viral titers and clinical response pattern-A first case-series
- 366 experience. *J Med Virol*, 2023 ; 95(1): e28181.
- 367 12. Tempestilli M, Mondì A, Matusali G, et al. Tecovirimat concentrations and viral suppression
- 368 in seminal fluid from patients with mpox. *Lancet Infect Dis*, 2023 ; 23(5): 531-532.
- 369 13. Hermanussen L, Brehm TT, Wolf T, et al. Tecovirimat for the treatment of severe Mpox in
- 370 Germany. *Infection*, 2023 : 1-6.

- 371 14. Seifu L, Garcia E, McPherson TD, et al. Notes from the Field: Posttreatment Lesions After
372 Tecovirimat Treatment for Mpox - New York City, August-September 2022. MMWR Morb
373 Mortal Wkly Rep, 2023 ; 72(17): 471-472.
374
375

Table 1. Demographic and clinical characteristics of enrolled patients.

Characteristic	No. (%)
Total	19 (100)
Man	19 (100)
Asian	17 (89.4)
White	1 (5.3)
Black	1 (5.3)
Age (median [IQR])	38.5 [31.8, 43.0]
History of STI	13 (68.4)
Syphilis	9 (69.2)
Gonorrhoeae	4 (30.8)
Chlamydia	5 (38.5)
Condyloma acuminata	1 (7.7)
HIV	10 (52.6)
CD4 counts < 200/ μ L	0 (0)
History of smallpox vaccination	0 (0)
Severe illness *	16 (84.2)
Patients with risk factors for severe illness †	0 (0)

Symptoms	
Rash	18 (94.7)
Fever (Body Temperature $\geq 38.5^{\circ}\text{C}$)	7 (36.8)
Chills	1 (5.3)
Lymphadenopathy	8 (42.1)
Malaise	8 (42.1)
Myalgia	2 (10.5)
Severe weakness	5 (38.5)
Headache	5 (38.5)
Back pain	1 (5.3)
Rectal pain	8 (42.1)
Pus or blood in stools	4 (30.8)
Abdominal pain	0 (0)
Tenesmus	5 (38.5)
Vomiting or nausea	0 (0)
Rash sites	
Genitals	5 (27.8)
Arms	12 (66.7)

Face	12 (66.7)
Legs	12 (66.7)
Perianal	8 (44.4)
Mouth, lips, or oral mucosa	4 (22.2)
Palms of hands	4 (22.2)
Trunk	14 (77.8)
Hip	8 (44.4)
Neck	7 (38.9)
Head	1 (5.6)
Soles of feet	4 (22.2)

376 Abbreviations: STI, sexually transmitted infection; HIV, human immunodeficiency virus; IQR,
377 interquartile range.

378 * Severe illness is defined as one or more of the following: hemorrhagic lesions such as rectal
379 bleeding; large number of skin lesions (>100) with fusions (including disseminated lesions);
380 viral or bacterial sepsis; encephalitis or myelitis caused by mpox; ocular or periorbital lesions
381 caused by mpox; requiring hospitalization; involvement of anatomical areas that could lead to
382 serious sequelae (e.g., pharyngeal, penile, vulvar, vaginal, urethral, rectal or anal lesions,
383 especially those requiring surgical intervention such as debridement).

384 † Risk factors for severe illness include the following: immunocompromised status (CD4
385 $<350/\text{mm}^3$ or HIV infection with uncontrolled viral load; primary immunodeficiency syndrome;
386 under drug therapy for solid tumors and hematologic tumors; on immunosuppressive therapy for
387 solid organ or pancreatic islet transplantation; under treatment with high-dose steroids [e.g.,
388 corticosteroid equivalent to ≥ 20 mg of prednisone per day for ≥ 2 weeks]; using alkylating
389 agents, antimetabolites, transplant-associated immunosuppressants, chemotherapeutic agents
390 classified as severely immunosuppressive, TNF inhibitors, or other immunosuppressive or
391 immunomodulatory biologics; and chimeric antigen receptor T-cell therapy or hematopoietic
392 cell transplantation [within 2 years after transplant or undergoing immunosuppressive therapy]);
393 children; pregnant and lactating women; patients with atopic dermatitis or exfoliative dermatitis.
394

395 Table 2. Clinical outcomes of the enrolled patients

	n (%)
Withdraw from the study (n=19)	5 (26.3)
<Primary endpoints>	
Negative PCR results (Ct value ≥ 40) for skin lesion specimens at 14 days after inclusion in the study (n=15)	9 (60.0)
<Secondary endpoints>	
Mortality	
14 days (n=15)	0 (0)
30 days (n=14)	0 (0)
Duration of fever ($\geq 37.5^\circ\text{C}$) (n=19)	
0 day	15 (78.9)
1 day	2 (10.5)
3 days	1 (5.3)
9 days	1 (5.3)
The general condition at entry (n=19)	
Total ambulation	19 (100)

Partial bedridden	0 (0)
Total bedridden	0 (0)
The general condition at 14 days (n=15)	
Total ambulation	16 (100)
Partial bedridden	0 (0)
Total bedridden	0 (0)
The general condition at 30 days (n=14)	
Total ambulation	14 (100)
Partial bedridden	0 (0)
Total bedridden	0 (0)
Adverse events (n=14)	0 (0)
Duration of hospitalization, days (n=14, median [IQR])	14 [14, 15]
Time from onset of rash until disappearance of rash, days (n=13, median [IQR])	24 [16, 31]
Opioids used for analgesia (n=14)	2 (14.2)

396 Abbreviations: PCR, polymerase chain reaction; IQR, interquartile range.

397

399 Table 3. Results of Tobit regression model analysis

Parameter	Coefficient	95% CI	<i>P</i> value
Positive HIV status	-4.88	-9.21 to -0.55	0.027
Severe symptoms	-5.17	-11.31 to 0.97	0.099
Days from symptom onset	1.34	0.98 to 1.69	< 0.001
Days from symptom onset to tecovirimat administration	-1.67	-2.44 to -0.90	< 0.001

400 Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus

401

402

403 **Figure legends**

404

405 **Figure 1. Flowchart of patients' allocation**

406

407 **Figure 2. Predicted Ct values of samples from skin lesions according to the interval from the**
408 **day of symptom onset to the day of PCR testing**

409 The blue line illustrates the predicted Ct values, while the gray areas denote the 95% confidence
410 intervals. The black dots represent the empirical data.

411 Ct; cycle threshold, PCR; polymerase chain reaction

412

413




Figure 1. Flowchart of patients' allocation. Patients opted for either Tecovirimat group or control group.

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.17.23294241>; this version posted August 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](#).

